Seeking Alpha

TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen

TREMFYA ® offers the flexibility of self-administration from the start of treatment, building on the prior approval of subcutaneous induction in Crohn's disease TREMFYA ® achieved significant rates of ...
Benzinga.com

Johnson & Johnson's Tremfya Seeks Expanded Use Approval After It Shares Encouraging Late-Stage Study Data In Crohn's Disease

On Monday, Johnson & Johnson (NYSE:JNJ) announced results from the Phase 3 GRAVITI study of Tremfya (guselkumab) for Crohn’s disease. The findings demonstrated significant clinical remission and ...
Pharmaceutical Technology on MSN

JPM26: J&J leans on immunology launches to fuel annual growth

Tremfya and Icotide are touted as key growth drivers in J&J’s strongly performing innovative medicines business.
Morningstar

New long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis

First-line treatment with TREMFYA® shows significant inhibition of radiographic progression at Week 24, which was sustained through Week 48, preserving joint health with a well-established safety ...
Seeking Alpha

TREMFYA® (guselkumab) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson's leadership in inflammatory ...

"Treatment with TREMFYA resulted in significant improvement in the chronic symptoms of ulcerative colitis, and importantly, normalization in the endoscopic appearance of the intestinal lining," said ...
KXAN

TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to significantly reduce both the signs and symptoms and the progression of structural damage in adults living with ...

TREMFYA ® demonstrated clinically meaningful and statistically significant efficacy in patients with active psoriatic arthritis at risk for structural damage in Phase 3b study Topline results ...
Healio

Tremfya nabs FDA approval for active ulcerative colitis, chasing competitor Skyrizi

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Johnson & Johnson’s Tremfya, a dual acting interleukin-23 inhibitor, for the treatment of ...
Nasdaq

J&J (JNJ) Seeks Expanded Use of Tremfya for Ulcerative Colitis

Johnson & Johnson JNJ has announced the submission of a supplemental biologics license application (sBLA) seeking approval of its immunology medicine, Tremfya, for a new indication — moderately to ...